suma/抗真菌药

The present invention concerns the preparation of new addition compounds of guanidinoacetic acid. They have improved physiological and therapeutic properties and are suitable for use as food supplements, animal feeds and in cosmetic or dermatological preparations in which especially their marked

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to acid addition salts of 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydr othieno[3,2-c]pyridine (preferably the hydrochloride or maleate) which exhibit excellent oral absorption,

The invention relates to acid addition salts of allylamine antimycotics. It concerns salts of the compound of formula I ##STR00002## with malic acid, i.e. (E)-N-methyl-6,6-dimethyl-N-(1-naphthylmethyl)hept-2-en-4-inyl-1-amine in malic acid addition salt form, hereinafter briefly named "the compounds

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is a U.S. National Phase of International Patent Application No. PCT/JP2015/072990, filed Aug. 17, 2015, which claims priority to Japanese Patent Application No. 2014-165622, filed Aug. 18, 2014, the entireties of which are incorporated

The present invention relates to the novel addition compound between econazole and acexamic acid, having formula (I) ##STR1## The present invention relates also to processes for preparing compound (I) as well as pharmaceutical compositions containing compound (I) as the active principle,

CROSS-REFERENCE TO RELATED APPLICATIONS This patent application is the U.S. national phase of International Patent Application No. PCT/JP2016/067405, filed Jun. 10, 2016, which claims the benefit of Japanese Patent Application No. 2015-119785, filed on Jun. 12, 2015, which are incorporated by

This is a .sctn.371 of PCT/EP2006/001908 filed Mar. 2, 2006, which claims priority from German Patent Application Nos. 10 2005 009 990.4 filed Mar. 4, 2005. The present invention concerns the preparation of new salts, addition compounds and complex compounds of guanidinoacetic acid. They have

This invention relates to a novel bis-(meta-amidinophenoxy)-compound and a pharmacologically acceptable acid addition salt thereof which is represented by the general formula: ##STR1## wherein A represents a chain residue selected from the group consisting of ##STR2## --CH.sub.2

This invention relates to a novel bis-(meta-amidinophenoxy)-compound and a pharmacologically acceptable acid addition salt thereof which is represented by the general formula: ##STR1## wherein A represents a chain residue selected from the group consisting of ##STR2## and --(CH.sub.2).sub.m --, in

FIELD OF THE INVENTION Description of the Text File Submitted Electronically The contents of the text file submitted electronically herewith are incorporated by reference in their entirety. A computer readable format copy of the Sequence Listing (filename: NEWL_012_05US_SeqList.txt, date recorded

FIELD OF THE INVENTION Description of the Text File Submitted Electronically The contents of the text file submitted electronically herewith are incorporated by reference in their entirety. A computer readable format copy of the Sequence Listing (filename: NEWL.sub.--012.sub.--02US_SeqList.txt, date

FIELD OF THE INVENTION The present invention relates to methods and compositions for treating cancer by stimulating humoral and cellular immune responses against tumor cells. In particular, this invention is directed to methods and compositions to enhance the humoral and cellular immunogenicity of

FIELD OF THE INVENTION Description of the Text File Submitted Electronically The contents of the text file submitted electronically herewith are incorporated by reference in their entirety. A computer readable format copy of the Sequence Listing (filename: NEWL.sub.--012.sub.--03US_SeqList.txt, date

BACKGROUND OF THE INVENTION This invention relates in general to fluorescence polarization immunoassays (FPIA) and modifications of current processes for detection of several commonly abused drugs in biological fluid wherein sequential or simultaneous performance of more than one FPIA assay is

BACKGROUND OF THE INVENTION Biological fluids such as blood plasma or serum, milk whey, urine, etc. contain a mixture of several proteins. For example, blood plasma contains albumin (3.5-4.5 g/100 ml, M. wt 66,000), fibrinogen (0.20-0.45 g/100 ml, M. wt 340,000), .alpha.-globulins (0.4-1.0 g/100 ml)